JPWO2019175802A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175802A5 JPWO2019175802A5 JP2020571917A JP2020571917A JPWO2019175802A5 JP WO2019175802 A5 JPWO2019175802 A5 JP WO2019175802A5 JP 2020571917 A JP2020571917 A JP 2020571917A JP 2020571917 A JP2020571917 A JP 2020571917A JP WO2019175802 A5 JPWO2019175802 A5 JP WO2019175802A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- pharmaceutical composition
- cxcr4
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024067425A JP2024105305A (ja) | 2018-03-13 | 2024-04-18 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642313P | 2018-03-13 | 2018-03-13 | |
| US62/642,313 | 2018-03-13 | ||
| PCT/IB2019/052042 WO2019175802A1 (en) | 2018-03-13 | 2019-03-13 | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067425A Division JP2024105305A (ja) | 2018-03-13 | 2024-04-18 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021517588A JP2021517588A (ja) | 2021-07-26 |
| JP2021517588A5 JP2021517588A5 (https=) | 2022-06-06 |
| JPWO2019175802A5 true JPWO2019175802A5 (https=) | 2022-06-06 |
| JP7561631B2 JP7561631B2 (ja) | 2024-10-04 |
Family
ID=66286540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571917A Active JP7561631B2 (ja) | 2018-03-13 | 2019-03-13 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
| JP2024067425A Withdrawn JP2024105305A (ja) | 2018-03-13 | 2024-04-18 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067425A Withdrawn JP2024105305A (ja) | 2018-03-13 | 2024-04-18 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230181635A1 (https=) |
| EP (1) | EP3765519B1 (https=) |
| JP (2) | JP7561631B2 (https=) |
| KR (1) | KR102693317B1 (https=) |
| CN (1) | CN112513079A (https=) |
| ES (1) | ES2973728T3 (https=) |
| WO (1) | WO2019175802A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| CN117715647A (zh) * | 2021-04-08 | 2024-03-15 | 埃迪瓦生物治疗公司 | 用nk细胞和cd38靶向抗体治疗癌症 |
| CN115836666B (zh) * | 2021-09-20 | 2024-11-01 | 上海中医药大学附属龙华医院 | 原位骨肉瘤和肺转移瘤小鼠模型及其制法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2532399T3 (es) | 2003-03-05 | 2015-03-26 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
| KR101722261B1 (ko) * | 2006-10-02 | 2017-04-03 | 메다렉스, 엘.엘.시. | Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도 |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| EA201071300A1 (ru) | 2008-05-14 | 2011-06-30 | Эли Лилли Энд Компани | Антитела к cxcr4 |
| US7892546B2 (en) | 2008-05-14 | 2011-02-22 | Eli Lilly And Company | Anti-CXCR4 antibodies |
| EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| US8877182B2 (en) * | 2009-03-26 | 2014-11-04 | Cellprotect Nordic Pharmaceuticals Ab | Expansion of NK cells |
| US20140120555A1 (en) * | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
| WO2013013025A2 (en) | 2011-07-20 | 2013-01-24 | Medimmune Limited | Anti-cxcr4 antibodies and methods of use |
| SG11201401386XA (en) | 2011-11-09 | 2014-10-30 | Bristol Myers Squibb Co | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
| PE20160671A1 (es) | 2013-08-02 | 2016-07-09 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco |
| EP3066129B1 (en) | 2013-11-06 | 2019-06-19 | Bristol-Myers Squibb Company | Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody |
| EP3212227B1 (en) * | 2014-10-28 | 2020-01-15 | Children's University Hospital Tübingen | Treatment of pediatric bcp-all patients with an anti-kir antibody |
| US10813952B2 (en) * | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| EP3307778A1 (en) | 2015-06-12 | 2018-04-18 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| TW201718851A (zh) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途 |
-
2019
- 2019-03-13 US US16/979,968 patent/US20230181635A1/en active Pending
- 2019-03-13 KR KR1020207029169A patent/KR102693317B1/ko active Active
- 2019-03-13 ES ES19719623T patent/ES2973728T3/es active Active
- 2019-03-13 JP JP2020571917A patent/JP7561631B2/ja active Active
- 2019-03-13 EP EP19719623.1A patent/EP3765519B1/en active Active
- 2019-03-13 CN CN201980018712.7A patent/CN112513079A/zh active Pending
- 2019-03-13 WO PCT/IB2019/052042 patent/WO2019175802A1/en not_active Ceased
-
2024
- 2024-04-18 JP JP2024067425A patent/JP2024105305A/ja not_active Withdrawn